GEMTESA Drug Patent Profile

When do Gemtesa patents expire, and when can generic versions of Gemtesa launch?

Gemtesa is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-two patent family members in forty-eight countries.

The generic ingredient in GEMTESA is vibegron. One supplier is listed for this compound. Additional details are available on the vibegron profile page.

DrugPatentWatch^® Generic Entry Outlook for Gemtesa

Gemtesa was eligible for patent challenges on December 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for GEMTESA

International Patents:	122
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	3
Patent Applications:	123
Drug Prices:	Drug price information for GEMTESA
What excipients (inactive ingredients) are in GEMTESA?	GEMTESA excipients list
DailyMed Link:	GEMTESA at DailyMed

See drug prices for GEMTESA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GEMTESA

Constraining patent/regulatory exclusivity:

8,653,260

NDA:

213006

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GEMTESA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	PHASE3
University of Missouri-Columbia	EARLY_PHASE1
Urovant Sciences GmbH	Phase 4

See all GEMTESA clinical trials

Pharmacology for GEMTESA

Drug Class	beta3-Adrenergic Agonist
Mechanism of Action	Adrenergic beta3-Agonists

Paragraph IV (Patent) Challenges for GEMTESA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GEMTESA	Tablets	vibegron	75 mg	213006	4	2024-12-23

US Patents and Regulatory Information for GEMTESA

GEMTESA is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,653,260.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,102,638
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	8,247,415		Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,357,636
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,180,219		Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	8,653,260			Y

International Patents for GEMTESA

When does loss-of-exclusivity occur for GEMTESA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Georgia, Republic of

Honduras

Hong Kong

Israel

Japan

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Norway

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GEMTESA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018282104
Australia	2024204591
Brazil	112019025636
Canada	3064989	UTILISATION DE VIBEGRON DANS LE TRAITEMENT DE LA VESSIE HYPERACTIVE (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER)
Chile	2019003533	Uso de vibegron para tratar vejiga sobreactiva.
China	110869022	使用维贝隆以治疗膀胱过度活动症 (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER)
China	117695286	使用维贝隆以治疗膀胱过度活动症 (Use of viberon to treat overactive bladder)

Supplementary Protection Certificates for GEMTESA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2276756	301305	Netherlands		PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1822 20240628
2276756	CA 2024 00054	Denmark		PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628
2276756	LUC00366	Luxembourg		PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628
2276756	CR 2024 00054	Denmark		PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628
2276756	122024000082	Germany		PRODUCT NAME: VIBEGRON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1822 20240627
2276756	C20240046	Finland
2276756	2024C/551	Belgium		PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628

GEMTESA (vibegron) Market Dynamics and Financial Trajectory (2019–2026): Uptake, Pricing, Competition, and Cash-Flow Drivers

Last updated: June 14, 2026

Gemtesa (vibegron) is positioned in the overactive bladder (OAB) market as a once-daily, beta-3 adrenergic agonist launched in the U.S. in 2019. Post-launch uptake has been shaped by payer coverage and formulary tiering, incremental clinical differentiation versus antimuscarinics, and competitive pressure from both next-wave OAB drugs and entrenched agents. Financial trajectory is primarily driven by U.S. net sales growth, mix shift toward higher-coverage channels, and the pace of share gains amid generics entering older OAB classes and persistent brand competition.

What is the commercial profile of GEMTESA (vibegron) in the OAB market?

Answer: Gemtesa targets symptomatic OAB patients (overactive bladder with urgency, with or without urge urinary incontinence, and with or without urinary frequency). Commercial performance is linked to formulary inclusion by large pharmacy benefit managers (PBMs), patient persistence for daily oral therapy, and prescriber switching from antimuscarinics and mirabegron.

Which OAB therapies does GEMTESA compete with?

• Antimuscarinics (generic and brand): solifenacin, oxybutynin, tolterodine, trospium, fesoterodine.
• Beta-3 agonists: mirabegron (Myrbetriq; multiple competitors, including generics where applicable) and other beta-3 candidates depending on geography and time period.
• Combination and sequencing strategies used by payers: switching within OAB classes based on step therapy and intolerance.

How do formulary dynamics drive Gemtesa revenue?

• Coverage and step edits determine initial penetration and refill rates.
• Payer tier placement impacts patient affordability and adherence.
• Clinical criteria in medical policy (eg, requirement for symptom documentation) can slow uptake in some segments.
• PBM rebates and contracting affect net price trajectory, not just list price.

How has GEMTESA gained market share since launch?

Answer: Share gains are typically gradual in OAB due to entrenched prescriber habits, patient tolerability issues, and payer-driven step therapy. For Gemtesa, momentum is influenced by the perceived tolerability profile versus antimuscarinics (lower anticholinergic burden) and the convenience of once-daily dosing.

Adoption pattern typical for OAB branded launches

• Early phase (first 12–24 months): coverage expansion, prescriber familiarity, and initial patient selection.
• Mid phase: persistence-driven repeat prescribing and incremental share capture from antimuscarinic discontinuers.
• Later phase: increased competition from other beta-3 agonist offerings and intensified generic substitution in older antimuscarinic classes.

What key commercial indicators reflect uptake?

• TRx and script velocity in key commercial classes.
• Net sales per treated patient as coverage broadens.
• Channel mix: retail vs specialty/limited distribution (where applicable).
• Persistence and discontinuation rates: oral OAB brands are sensitive to tolerability and symptom control durability.

How do net pricing and rebate economics affect GEMTESA financials?

Answer: Net sales for Gemtesa are the net of rebates, discounts, chargebacks, and wholesaler inventory dynamics. Pricing pressure is mostly indirect, driven by contracting intensity and competitive therapeutic alternative availability rather than direct price cuts.

What factors compress or expand net price?

• Payer mix shifts toward larger accounts with aggressive rebate requirements.
• Formulary wins that reduce patient out-of-pocket friction.
• Therapeutic interchange policies and step therapy that limit use in lower-coverage populations.
• Competitive contracting by alternative beta-3 or combination regimens.

How does mix shift change profitability?

• Higher volume in better-covered channels can improve gross-to-net and distribution economics.
• Conversely, broad access can increase reimbursement pressure if payers demand deeper concessions.

When does competitive pressure intensify for GEMTESA?

Answer: Competitive pressure intensifies when (1) alternative OAB options receive broader coverage, (2) formulary restrictions loosen for competitors, or (3) generics erode the economic appeal of antimuscarinics, shifting the competitive center of gravity toward beta-3 agents and combination strategies.

What competition shocks matter most?

• Generic erosion of older antimuscarinics changes the “default” step therapy pathway and influences switching.
• New beta-3 entrants or expanded indications for existing beta-3 agents shift formulary decision models.
• Safety and tolerability comparisons influence formulary committees and physician selection.

What is the financial trajectory risk for GEMTESA (vibegron)?

Answer: The primary financial risk is slower-than-expected share capture that delays scaling benefits, combined with sustained rebate pressure from aggressive payer contracting.

Risk categories that hit the income statement

• Revenue underperformance: lower uptake, slower switching, and weaker persistence.
• Margin compression: increased rebates and payer discounts if access is secured through concessions.
• Inventory and channel effects: wholesaler buying patterns and return flows can swing quarterly net sales.
• Litigation and regulatory costs: if IP or labeling disputes arise, they can impact cash flow and timing of commercialization.

How does patent and exclusivity structure influence GEMTESA sales duration?

Answer: Gemtesa is protected by a combination of composition and formulation-related patent layers and regulatory exclusivity around initial approval, which collectively shape how long branded economics persist before generic competition.

What matters for generic entry timing?

• Orange Book listing completeness for formulation, method-of-use, and manufacturing patents tied to the FDA-approved NDA.
• Patent-for-patent challenges (Paragraph IV) can accelerate generic launch.
• Settlement structures can delay entry even if a challenge is filed.

What is the Orange Book status of GEMTESA and how does it affect generic risk?

Answer: Generic risk depends on the remaining patent term for each listed patent in the FDA Orange Book and whether any are subject to active Paragraph IV litigation or settlements. The nearer-term launch window is usually set by the earliest expiring relevant patent plus any exclusivity remaining.

How to interpret Orange Book listings for commercialization timelines

• “Drug product” vs “method” patents can block different generic workstreams.
• Formulation patents can keep generics off-market if they require bioequivalence-safe alternatives.
• Method-of-use patents can restrict label and indication-specific substitution.

What FDA pathway and label scope influence GEMTESA commercial reach?

Answer: Gemtesa’s label scope determines coverage eligibility, prescribing comfort, and substitution decisions at the PBM level. Broader label language increases the addressable population and can expand contracting outcomes.

What label constraints can reduce addressable volume?

• Requirements around symptom definitions, comorbidities, or prior therapy steps in payer medical policy.
• Differences between U.S. label wording and real-world prescribing interpretations.

How does GEMTESA compare to Myrbetriq and antimuscarinics in prescribing economics?

Answer: Gemtesa competes on tolerability and convenience while mirabegron competes as an established beta-3 option. Antimuscarinics compete on price, now often constrained by generics but still influenced by tolerability.

Prescriber decision drivers

• Perceived side effect profile and patient preference.
• Prior response to beta-3 vs antimuscarinics.
• Dose titration requirements and adherence.

What competitive scenarios could change Gemtesa revenue curve shape?

Answer: The steepness of the revenue curve is sensitive to payer inclusion breadth and the speed at which physicians switch and maintain long-term therapy.

Scenario A: continued formulary broadening

• Faster TRx growth and improving persistence lift net sales.
• Rebates may rise, but the absolute revenue scale can offset margin drag.

Scenario B: tighter step edits and rebate pressure

• Growth slows and shifts to higher-acuity or less price-sensitive subsegments.
• Margin compresses due to payer concessions.

Scenario C: intensified beta-3 competition

• Share gains slow and advertising/medical spend may need to rise to defend positioning.
• Net price remains pressured as PBMs benchmark beta-3 options.

What manufacturing and supply chain dynamics could affect GEMTESA financial performance?

Answer: In OAB branded oral solids, the main supply-driven financial issues are service levels, batch release timing, and quality events that can disrupt quarterly sales.

Operational levers

• Fill-finish reliability and bulk API availability.
• Quality system stability and release timelines.
• Distribution efficiency affecting chargebacks and returns.

Key monetization drivers for GEMTESA’s cash flow

Answer: Cash flow is tied to the gap between gross invoice price and net realized revenue, offset by operating expenses and working capital swings.

Cash-flow levers

• Net sales realization: rebates and chargebacks.
• Working capital: receivables from wholesalers, inventory normalization.
• Expense scale: SG&A and medical spend as sales ramp.
• Tax and one-time items: can affect reported cash conversion.

Key takeaways

• Gemtesa’s market dynamics are dominated by payer formulary contracting, patient persistence, and beta-3 competitive benchmarking rather than direct list-price changes.
• The financial trajectory is most sensitive to net sales growth vs rebate intensity and to the speed of share capture from antimuscarinics and mirabegron.
• Generic pressure timing is governed by Orange Book patent layering and exclusivity, plus Paragraph IV/settlement events that can alter when generic substitution becomes feasible.

FAQs

1. How do step edits and prior authorization policies typically affect Gemtesa uptake in commercial formularies?
2. What generic entry scenarios most likely accelerate price pressure for vibegron in the U.S.?
3. Which therapeutic comparisons (beta-3 vs antimuscarinics) most influence PBM coverage decisions for Gemtesa?
4. How does channel mix change (retail vs specialty/limited distribution) impact Gemtesa net sales accounting?
5. What operational risks (quality, batch release, API supply) most often drive quarter-to-quarter branded oral drug revenue volatility?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-14).
2. FDA. Drugs@FDA: FDA-approved drug products for vibegron (Gemtesa). (Accessed 2026-06-14).

DrugChatter Q&A for GEMTESA

Is gemtesa available in australia?
Does gemtesa have a generic?
Gemtesa price without insurance?
Gemtesa patient assistance program?
Why is gemtesa so expensive?